NCT01545843

Brief Summary

The purpose of the study is to determine whether changing sleep patterns improves response to an antidepressant medication.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P25-P50 for phase_2 depression

Timeline
Completed

Started Mar 2009

Typical duration for phase_2 depression

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2009

Completed
2.9 years until next milestone

First Submitted

Initial submission to the registry

January 12, 2012

Completed
2 months until next milestone

First Posted

Study publicly available on registry

March 7, 2012

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
2.2 years until next milestone

Results Posted

Study results publicly available

January 30, 2015

Completed
Last Updated

January 30, 2023

Status Verified

January 1, 2023

Enrollment Period

3.8 years

First QC Date

January 12, 2012

Results QC Date

January 13, 2015

Last Update Submit

January 25, 2023

Conditions

Keywords

depressionsleeptreatment

Outcome Measures

Primary Outcomes (1)

  • Hamilton Rating Scale for Depression-17 Item Minus Sleep Items

    Total score on a clinician-rated measure of depressive symptoms, minus 3 sleep items Total score range: 0-46. Higher scores represent more severe depression.

    Post-treatment (8 weeks)

Secondary Outcomes (7)

  • Quick Inventory of Depressive Symptoms (QIDS)

    Post-treatment (8 weeks)

  • Pittsburgh Sleep Quality Index

    Baseline, 2 weeks and 8 weeks post-treatment

  • Change in EEG Sleep Measures I: Total Sleep Time

    Baseline, 2 weeks, 8 weeks

  • Change in EEG Sleep Measures II (Sleep Efficiency)

    Baseline, 2 weeks, 8 weeks

  • Change in Neuropsychological Functioning: Memory

    Baseline, 2 weeks, 8 weeks

  • +2 more secondary outcomes

Study Arms (3)

No sleep deprivation

ACTIVE COMPARATOR

Sleep scheduling plus fluoxetine. 8 hours time in bed for two weeks plus fluoxetine for 8 weeks

Behavioral: Sleep schedulingDrug: Fluoxetine

Late bedtime sleep deprivation

EXPERIMENTAL

Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.

Behavioral: Sleep schedulingDrug: Fluoxetine

Early risetime sleep deprivation

EXPERIMENTAL

Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Risetime advanced by 2 hours.

Behavioral: Sleep schedulingDrug: Fluoxetine

Interventions

8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime

Early risetime sleep deprivationLate bedtime sleep deprivationNo sleep deprivation

20-40 mg fluoxetine daily for 8 weeks

Also known as: Prozac
Early risetime sleep deprivationLate bedtime sleep deprivationNo sleep deprivation

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Between 18 and 65 years old
  • Current major depressive episode
  • Habitual TIB of 7 to \< 10 hours
  • No antidepressant medications for ≥ 2 weeks (4 weeks for MAOIs or longer acting antidepressants)
  • Score of at least 18 on the Hamilton Rating Scale of Depression

You may not qualify if:

  • Alcohol or substance abuse/dependence in past 6 months
  • Current posttraumatic stress disorder or bulimia nervosa (past 6 months)
  • Lifetime history of bipolar I or II disorder, schizophrenia/other psychotic disorder, and anorexia nervosa
  • Trials of fluoxetine in the past 6 months
  • Medical disorders or pain syndromes that may affect sleep or are associated with significant depression (e.g. thyroid or Cushing's disease); history of head trauma with loss of consciousness of \> 5 minutes; history of seizures
  • Sleep disorders other than insomnia, such as sleep apnea and periodic limb movement disorder
  • Current use of prescription, over-the-counter, or naturopathic remedies for sleep (e.g., barbiturates, benzodiazepine agonists, nonbenzodiazepine hypnotics, analgesics) or depression (e.g., Sam-E, St. John's Wort)
  • Currently working evening or midnight shift (subjects who have recently traveled across multiple time zones will be included at the discretion of the PI).
  • Currently at risk for drowsy driving or employment that requires routine operation of transportation vehicles (e.g., truck/taxi driver, airline pilot) or hazardous equipment.
  • Known allergy, hypersensitivity or contraindication to study medication
  • Females: pregnant or nursing

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Related Publications (1)

  • Arnedt JT, Swanson LM, Dopp RR, Bertram HS, Mooney AJ, Huntley ED, Hoffmann RF, Armitage R. Effects of Restricted Time in Bed on Antidepressant Treatment Response: A Randomized Controlled Trial. J Clin Psychiatry. 2016 Oct;77(10):e1218-e1225. doi: 10.4088/JCP.15m09879.

MeSH Terms

Conditions

Depression

Interventions

Fluoxetine

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

PropylaminesAminesOrganic Chemicals

Limitations and Caveats

Sample is largely young, healthy adults

Results Point of Contact

Title
Dr. J. Todd Arnedt
Organization
University of Michigan

Study Officials

  • J. Todd Arnedt, Ph.D.

    University of Michigan

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Psychiatry

Study Record Dates

First Submitted

January 12, 2012

First Posted

March 7, 2012

Study Start

March 1, 2009

Primary Completion

December 1, 2012

Study Completion

December 1, 2012

Last Updated

January 30, 2023

Results First Posted

January 30, 2015

Record last verified: 2023-01

Locations